Gastrointestinal Center and Institute of Minimally Invasive Endoscopic Care (iMEC), Sano Hospital, Hyogo, Japan.
Department of Pathology, Shinko Hospital, Hyogo, Japan.
Dig Endosc. 2018 Apr;30 Suppl 1:45-50. doi: 10.1111/den.13055.
Magnifying chromoendoscopy has been one of the most reliable diagnostic methods for distinguishing neoplastic from non-neoplastic lesions. The aim of this prospective study was to clarify the clinical usefulness of magnifying chromoendoscopy for colorectal polyps initially diagnosed with low confidence (LC) by magnifying narrow-band imaging (NBI).
Consecutive adult patients who underwent total colonoscopic examination with magnifying NBI between July and December 2016 at Sano Hospital were prospectively recruited. Endoscopists were asked to carry out additional magnifying chromoendoscopy for cases that had been initially diagnosed as Japan NBI Expert Team (JNET) Type 1 or 2A with LC by magnifying NBI. We investigated the diagnostic performance of magnifying NBI for polyps diagnosed as JNET Type 1 or 2A with LC (first phase) and that of subsequent magnifying chromoendoscopy (second phase) in differentiating neoplasia from non-neoplasia.
In 50 patients, we analyzed 53 polyps classified as JNET Type 1 or 2A with LC prediction. Accuracy and negative predictive value of magnifying NBI (first phase) were 58.5% (95% CI, 44.1-71.9%) and 66.0% (95% CI, 36.6-77.9%), and those of magnifying chromoendoscopy (second phase) were 66.0% (95% CI, 51.7-78.5%) and 61.1% (95% CI, 43.5-76.9%), respectively.
Regardless of the findings of additional chromoendoscopy, all polyps should be resected and submitted for histopathological examination when the confidence level in differentiating adenomatous from hyperplastic polyps by magnifying NBI is low.
放大 chromoendoscopy 一直是鉴别肿瘤性和非肿瘤性病变最可靠的诊断方法之一。本前瞻性研究的目的是阐明放大 chromoendoscopy 在经放大窄带成像(NBI)最初诊断为低可信度(LC)的结直肠息肉中的临床应用价值。
连续纳入 2016 年 7 月至 12 月在佐野医院接受全结肠镜检查并进行放大 NBI 检查的成年患者。要求内镜医师对放大 NBI 最初诊断为日本 NBI 专家小组(JNET)1 型或 2A 型且 LC 的病例进行额外的放大 chromoendoscopy。我们研究了放大 NBI 对被诊断为 JNET 1 型或 2A 型且 LC 的息肉(第一阶段)的诊断性能,以及随后的放大 chromoendoscopy(第二阶段)在鉴别肿瘤性和非肿瘤性方面的诊断性能。
在 50 例患者中,我们分析了 53 个被归类为 JNET 1 型或 2A 型且 LC 预测的息肉。放大 NBI(第一阶段)的准确性和阴性预测值分别为 58.5%(95%CI,44.1-71.9%)和 66.0%(95%CI,36.6-77.9%),放大 chromoendoscopy(第二阶段)的准确性和阴性预测值分别为 66.0%(95%CI,51.7-78.5%)和 61.1%(95%CI,43.5-76.9%)。
无论额外 chromoendoscopy 的结果如何,当通过放大 NBI 区分腺瘤性和增生性息肉的可信度较低时,所有息肉均应切除并提交组织病理学检查。